Pharmacological interventions, including renin–angiotensin system antagonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors and novel mineralocorticoid receptor blockers are valuable in managing these complex conditions, although frequently difficult or impossible to use in advanced kidney disease. Here, NR3C2 is linked to kidney disorder.